Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ripasudil after descemetorhexis in Fuchs endothelial corneal dystrophy
2017-002490-19Phase 2Completed
- Sponsor
- Universitätsklinikum Erlangen
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in Fuchs endothelial dystrophy (FED) comparing Ripasudil with Placebo (2 arms). Primary endpoint: Incidence of adverse reactions and serious adverse reactions. Started Jun 2017; status: completed.
02
Drugs
ripasudil
03
Conditions
Fuchs endothelial dystrophy (FED)
Beyond the preview
Go deeper on 2017-002490-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002490-19.